83 results about "Molecular typing" patented technology

The invention provides an EGFR wild-type lung adenocarcinoma prognosis risk assessment method based on multi-omics and machine learning, and the method comprises the steps: obtaining multi-omics and clinical data of lung adenocarcinoma, obtaining a data set, and carrying out the multi-omics consensus clustering, and obtaining a molecular typing result; high-risk subtype specific candidate genes are identified, a candidate prognosis gene set is obtained, multi-algorithm machine learning comparison optimization is carried out, and a modeling strategy is obtained; performing feature screening and model training to obtain a multi-omics feature model so as to calculate an individual risk score of the to-be-tested sample; the individual risk score and the clinical staging information are utilized to obtain a clinical column diagram and a survival prediction result, then the flow of the multi-omics feature model, the individual risk score and the survival result is Web to obtain a clinical system, and a lung adenocarcinoma prognosis risk assessment result is output. The invention can realize an objective, accurate, generalizable and multifunctional prognosis evaluation and treatment guidance tool, and has important clinical application value and wide industrialization prospect.

The invention discloses a glioma radiotherapy postoperative risk assessment method based on a magnetic resonance image, particularly relates to the field of glioma radiotherapy patient health risk assessment, and is used for solving the problem that an existing assessment mode depends on manual interpretation and is difficult to predict bad clinical outcomes in advance. The method comprises the following steps: performing clinical data gridding reconstruction on a corticoid use cycle of a patient and tumor molecular typing, and combining morphological characteristics of an edema region in a magnetic resonance image to generate time-aligned clinical comprehensive characteristic vectors; mining a frequent association item set between the comprehensive feature vector and the pathological process to construct a mapping relation model; establishing a probability graph reasoning model of the bad outcome based on the pathological process vector sequence and the probability weight; and integrating the two types of models to form a causal reasoning network, and inputting a target patient feature vector to calculate an accumulated risk value of reaching a bad outcome. According to the method, an interpretable individual risk assessment result can be output, and a basis is provided for postoperative follow-up visit and intervention.

The invention relates to the technical field of biology, and particularly discloses a tumor imaging biomarker quantitative analysis system based on multi-mode MRI voxel space coupling and application. According to the application, the spatial coupling relationship between blood brain barrier destruction and perfusion in a tumor can be quantitatively reflected through the voxel overlap region proportion of T1CE and CBF signals, the 1p / 19q state can be efficiently predicted, and accurate prediction of IDH mutation and WHO grading (2-3 grade vs.4 grade) is realized in cooperation with clinical factors, so that the application has a wide application prospect. And an efficient and potential noninvasive imaging biomarker is provided for ADG preoperative molecular typing and grading prediction.

The invention discloses a multi-modal medical image analysis system and method, and the system comprises a data obtaining and feature extraction module which is used for obtaining medical image data and clinical data of a patient, and extracting multi-modal features from the medical image data and the clinical data; the feature fusion and standardization module is used for performing decision-level fusion on the multi-modal features and performing standardization processing on the basis of pre-stored training set statistics so as to eliminate dimensional differences among different features and overcome the limitation of dependence on single-modal data in the prior art; and the multi-task prediction module is internally provided with a well-trained multi-task prediction model, can input the standardized multi-modal feature vectors at the same time, synchronously outputs prediction results of the muscular infiltration depth, histological type and molecular typing of the endometrial cancer, and outputs probability distribution corresponding to each prediction result at the same time. A built-in multi-task prediction model of the system adopts three independent parallel prediction paths, so that the comprehensiveness and the refinement degree of endometrial cancer preoperative evaluation are greatly improved.

The application provides a protein composition for predicting the prognosis effect of metastatic hormone-sensitive prostate cancer and application thereof, and belongs to the technical field of prognosis evaluation.The protein composition for predicting the prognosis effect of metastatic hormone-sensitive prostate cancer comprises protein molecules for evaluating drug resistance of a patient and protein molecules for evaluating sensitivity of the patient; the protein molecules for evaluating drug resistance of the patient comprise MCM4, NT5E, LTBP4, IAH1, HP, DOCK2 and EEF1A2; and the protein molecules for evaluating sensitivity of the patient comprise TFF3, FABP5 and LAMP2.The application constructs a molecular typing of mHSPC based on the above protein composition, evaluates the sensitivity of a mHSPC patient to ADT treatment in advance, and thus realizes precise treatment.

The invention discloses a method for constructing astrocytes serving as a smoke disease model, and belongs to the technical field of crossing of stem cells and neuroscience. The method comprises the following steps: S1) reprogramming CD34 + cells in in-vitro PBMCs (peripheral blood mononuclear cells) of smoke disease patients carrying and not carrying RNF213p.R4810K mutation to obtain induced pluripotent stem cells; and S2) directionally inducing and differentiating the induced pluripotent stem cells into astrocytes through a neural progenitor cell way, wherein the obtained astrocytes are the astrocytes capable of being used as the smoke disease model. The astrocyte model prepared by the invention can be used for researching pathogenesis, nerve-blood vessel interaction process and blood-brain barrier (BBB) related functions of smoke diseases, and can be further applied to molecular typing of diseases and in-vitro function evaluation of candidate drugs.

The invention relates to the technical field of biology, and provides a LanCL1 gene as a target for typing and prognosis of glioma. According to the application of the reagent for detecting LanCL1 gene expression in preparation of products for glioma molecular typing and prognosis prediction, molecular typing of glioma patients can be achieved, LanCL1 high expression is highly related to low malignancy and good prognosis, and clinical risk stratification, treatment decision and treatment assistance are facilitated.

The application relates to a high-throughput identification method of lncRNA coding peptides and application thereof, and belongs to the technical field of biology. The method combines a translationomics technology and a protein mass spectrometry technology, takes ribosome footprint sequencing data as a starting point, determines an open reading frame located on an lncRNA gene according to a three-base periodicity rule of a sequencing fragment, further constructs a proteogenomics index after systematic filtration, uses a computational proteomics method to detect an lncRNA translation event, and systematically identifies lncRNA coding peptides on the basis. The method has the characteristics of modularity and strong expandability, can be widely used for various types of proteome data, and can high-throughput identify and quantitatively detect lncRNA coding peptides. The application provides a prediction of molecular typing and prognosis of cancer patients based on an lncRNA coding peptide network model, and provides an important reference basis for precise medication of clinical patients.

The application discloses a molecular typing method of Staphylococcus capitis, and first establishes an operation technology for molecular typing of Staphylococcus capitis by using a multi-locus sequence typing system (MLST). Seven conservative gene fragments are confirmed by screening, all known Staphylococcus capitis genomes are typed based on the combined sequences, ST types and CC types are defined, and a system evolution tree based on core genome SNP differences is compared, so that reliable typing results can be obtained. Seven pairs of PCR primers are designed and verified, and the Staphylococcus capitis can be typed by MLST. The seven conservative gene combinations and amplification primers used in the typing technology are used for the first time, and the PCR reaction system and conditions are optimized by the inventors. The technical process can be used for molecular classification and epidemiological monitoring of Staphylococcus capitis.

The invention provides a 19F streptococcus pneumoniae invasiveness risk prediction method, and relates to the technical field of molecular biology. Wherein the evaluation marker combination comprises a translation genome, a cell synthesis genome and a ligand transport metabolism genome; the translation genome comprises rluB and rsmE; the cell synthetic genome comprises mscL and murI; and the ligand transport metabolism genome comprises czcD, site B, mtsC and pstS. The evaluation marker combination can accurately evaluate the invasive risk of serotype 19F streptococcus pneumoniae, and realizes molecular typing and risk prediction. The kit has high sensitivity and specificity, is suitable for high-throughput detection, and is helpful for clinical diagnosis and pathogenic mechanism research.

The invention belongs to the technical field of breast cancer molecular typing, and more specifically relates to a mammary gland ultrasound video HER2 expression state identification method based on spatial-temporal feature interaction. The method comprises the following steps: taking an original breast ultrasonic video as input data, performing multi-stage data preprocessing operation, and then performing data balance on training data to obtain a standardized training set; sequentially constructing a UniFormerV2 network-based feature module, a multi-stage feature fusion module and a classification module, and training to obtain a trained model; and inputting the test set into the model to obtain a final prediction result of the HER2 expression state. The problems that an existing HER2 detection method is invasive in operation and cannot perform dynamic monitoring, and an existing deep learning method based on static images neglects space-time dynamic information in an ultrasonic video, so that prediction accuracy of the HER2 expression state, especially HER2-Low subtype is insufficient are solved.

The invention relates to the field of clinical molecular typing, and discloses a novel PCOS subphenotype precise diagnosis and treatment platform, which comprises a case sample inclusion and queue construction module; a data acquisition and processing module; the key feature screening module is used for acquiring 12-dimensional feature data of the patient for sub-phenotype clustering; the unsupervised learning module is used for carrying out unsupervised clustering on the 12-dimensional feature data of the cases by adopting a K-Means clustering algorithm and dividing a PCOS patient group into five new subtypes; the XGBoost model construction module is used for constructing an XGBoost model by taking the five new subtypes as classification tags; and the typing prediction module is used for predicting the PCOS subphenotype by adopting the constructed XGBoost model. The invention provides a new set of fine-grained typing and prediction model and a subtype-based precise treatment scheme, and is suitable for subtype distinguishing and treatment guidance of PCOS patients.

The invention provides a bladder cancer subtype classification system and molecular typing method based on machine learning, and the molecular typing method comprises the steps: firstly obtaining transcriptome data and survival information of bladder cancer tissue of a patient, extracting data from a preset amino acid metabolism related gene set, and constructing a gene expression matrix; then, clustering the patients by adopting an unsupervised clustering algorithm, and determining at least two types of amino acid metabolism molecule subtypes in combination with a stability index; thirdly, carrying out survival difference analysis on different subtypes, screening out differential expression genes related to survival outcomes, constructing a survival prediction model based on the differential expression genes, and calculating amino acid metabolism scores of the patients; finally, the patients are grouped according to the scores, and molecular typing based on the amino acid metabolism characteristics is completed. According to the invention, stable and accurate typing of the bladder cancer patient is realized.

The invention discloses an oral lichen planus molecular subtype based on a serum protein marker. The molecular typing is based on a multi-center clinical queue, a new molecular typing is obtained by using transcriptome sequencing data through a Seed-Kmeans semi-supervised clustering algorithm, and a serum marker is further screened out through multiple omics data including the transcriptome sequencing data, proteome sequencing data and serum enzyme-linked immunosorbent assay experimental data. The method can be used for further judging molecular typing. The molecular typing can obviously improve the curative effect of the oral lichen planus medicine, and is beneficial to the realization of OLP individualized precision medical treatment.

The invention relates to the technical field of medical detection, and particularly discloses a biomarker combination for identifying cervical cancer molecular subtypes, a kit and application. The biomarker combination comprises a protein CDH13, a protein TP53BP1, a protein NNMT and a protein HSPB1, and molecular subtype correlation analysis is carried out on a sample by detecting relative expression characteristics of the proteins in a cervical cancer in-vitro sample. Based on the relative expression characteristics of each protein, a cervical cancer sample can be divided into at least one of an epithelial-mesenchymal transition related subtype, a proliferation related subtype, an immune response related subtype and an epithelial differentiation related subtype. The invention also provides a detection kit and an analysis system for realizing cervical cancer molecular subtype identification. According to the technical scheme, the cervical cancer can be subjected to molecular typing from the protein function execution level, a reliable technical means is provided for molecular typing research, prognosis evaluation and accurate treatment related research of the cervical cancer, and the application prospect is good.

The invention provides a kit for molecular typing and prognosis evaluation of salivary gland adenoid cystic carcinoma and application, and relates to the technical field of molecular pathological diagnosis. The invention provides application of a reagent for detecting long arm deletion of a chromosome 6 and / or long arm deletion of a chromosome 14 in preparation of a kit for molecular typing, risk stratification and / or prognosis evaluation of salivary gland adenoid cystic carcinoma. In the application, the defect of traditional pathological typing in prognosis evaluation of adenoid cystic carcinoma can be remarkably overcome by detecting long-arm deletion of the chromosomes 6 and 14, latent patients with morphological seemingly low risk but actually high risk such as sieve subtype can be accurately identified, and the accuracy of risk stratification is greatly improved. As an objective and independent molecular index, the method is helpful for guiding personalized diagnosis and treatment decisions, can be easily converted into a rapid and economic clinical conventional detection means, and has extremely high practical value.

The invention relates to an ATC histopathological molecular typing method based on knowledge distillation and computing equipment, in order to reproduce the characterization capability of a visual large model under clinical conventional computing power, a teacher-student distillation framework is constructed in the scheme, a basic large model of freezing parameters is used for guiding a lightweight model to capture complex pathological morphological characteristics, and the probability that the visual large model captures the complex pathological morphological characteristics is lowered. The problem that a high-precision model is difficult to deploy locally is effectively solved. Furthermore, in view of a strong nonlinear coupling relationship between a macroscopic form and a microscopic molecule, a deep fusion mechanism based on collaborative gating and bilinear interaction is introduced in the scheme, and the limitation that the co-occurrence enhancement effect between modes cannot be captured by traditional linear fusion is broken through. The mechanism can dynamically mine high-order interaction characteristics, so that high-precision and high-interpretability molecular subtype prediction is realized on the premise that expensive omics detection does not need to be continuously carried out.

The invention belongs to the field of biochemistry, and relates to a myocardial infarction risk assessment system, a kit and an instrument. The myocardial infarction risk assessment system obtains the content of a thiol metabolite combination in a biological sample of a subject, and outputs a risk score based on a preset myocardial infarction risk assessment model according to the content of the thiol metabolite combination. The method comprises the following steps of: presetting AUCgt of a myocardial infarction risk assessment model in a training set and two groups of external verification sets; 0.8, Plt; and the kit has good sensitivity, specificity and reliability. A myocardial infarction risk assessment system and a kit developed on the basis of the model can realize early screening, auxiliary diagnosis, illness monitoring and drug curative effect assessment of myocardial infarction on a conventional liquid chromatography-tandem mass spectrometry platform, and a new technical approach is provided for metabolic molecule typing and risk stratification of myocardial infarction.

The invention discloses a breast cancer treatment scheme decision-making method fusing agent cooperation and game theory modeling, and relates to the technical field of intelligent medical treatment, and the method comprises the steps: inputting a multi-sequence MRI image into an expert network, and obtaining a molecular typing result; according to a molecular typing result, a diagnosis and treatment guide and clinical text information of the patient, dividing into corresponding risk grades; adopting a Stackelberg game model to formulate a treatment scheme corresponding to the risk level, and for the low risk level LRT, formulating a treatment scheme through a single expert model; aiming at the middle risk level MRT, making a treatment scheme by adopting a prison dilemma game model; and aiming at the high-risk-level HRT, a treatment scheme is formulated by adopting a hunting deer game model. According to the method, the accuracy and reliability of breast tumor diagnosis decision are improved by combining the multi-modal patient information, the three-layer risk level, the large language model and the game theory driven multi-agent cooperation.

The application provides a microfluidic chip for diagnosing avian influenza H3 / H5 / H6 / H9 molecular typing based on microfluidics and a use method, relates to the field of pathogenic microorganism testing technology, and improves the efficiency, accuracy and convenience of avian influenza molecular diagnosis, promotes the development of molecular diagnosis technology, and uses the microfluidic chip body to be supported and used through the chip support, opens the protection layer attached to the microfluidic chip body by means of the light-proof assembly on the side, and can provide a light-proof environment again during and after the detection process, and can maintain a longer detection state.

The invention discloses a chlamydia psittaci cgMLST molecular typing method, and belongs to the field of microbial molecular typing and tracing. According to the invention, an operation technology for carrying out molecular typing on chlamydia psittaci by using a core genome multi-site sequence typing system (cgMLST) is established for the first time. The chlamydia psittaci cgMLST system is established through the processes of collecting chlamydia psittaci genomes in a disclosed genome database, obtaining core genomes through quality control screening and generic genome analysis, screening core genes suitable for typing under multiple screening conditions and the like. And comparing with a phylogenetic analysis result based on core genome SNP difference to confirm the resolution and reliability of the typing system. According to the typing technology, the core genome of the chlamydia psittaci is determined for the first time, and the typing technology can be used for molecular typing and epidemiological monitoring of the chlamydia psittaci.

The invention discloses a large model analysis system and method for endometrial cancer data management, and relates to the technical field of data large model analysis, and the method comprises the steps: determining the total amount of sample data; each group of sample data comprises characteristic data information of the patient and a judgment result of molecular typing data determined by adopting an immunohistochemical method; the features are divided based on the feature data information of the patient, the coincidence rate under each feature division is calculated, and a plurality of coincidence subintervals are formed based on the coincidence rates; and constructing a training model, forming the probability that the coincidence rate is in different coincidence subintervals based on different feature data information, forming a recommendation decision, and feeding back the recommendation decision to an administrator port. The method can solve the problem of significant subjectivity existing in a traditional mode of selecting a detection method only depending on the personal experience of doctors, establishes an objective decision standard through data driving, and reduces the selection deviation caused by the experience difference of the doctors.

The invention discloses a library construction method for non-HPV (human papillomavirus) related cervical tumor and precancerous lesion molecular subtypes thereof based on high-throughput sequencing, which comprises the following steps: ultrasonically breaking genome DNA (deoxyribonucleic acid) of a detected sample to obtain a DNA fragment, modifying the tail end, connecting a joint, and performing purification and pre-amplification reaction, namely performing hybridization reaction on a pre-amplification sequence by using a hybridization capture reagent, according to the method, a hybridization capture reagent is adopted, DNA fragments combined through non-specific capture are enriched and removed, then an amplification reaction is carried out, a library is obtained, next-generation sequencing is carried out, original data are subjected to bioinformatics analysis, variation information is obtained, and the hybridization capture reagent comprises specific primers with the sequences shown as SEQ ID NO: 1-175. According to the present invention, the integration of the non-HPV-related cervical tumor and precancerous lesion molecule detection is achieved, the detection can be completed in one experiment, and the sequencing depth is improved by specifically enriching the target region so as to improve the sensitivity of the non-HPV-related cervical tumor and precancerous lesion molecule detection.

The invention belongs to the technical field of tumor molecular biology, and discloses a digestive tract tumor cross-cancer-species molecular typing method and application thereof. According to the method, six-dimensional molecular characteristics are integrated by using a robust rank polymerization algorithm, and high-confidence functional genes are screened through RNAi and CRISPR dual verification, so that the problems of single dimension and insufficient specificity of traditional screening are solved, the functional gene screening is more accurate, and a reliable foundation is laid for typing; the method has the advantages that tissue origin limitation is broken through, unified typing of the generic gastrointestinal tumors is realized, stability is verified in multi-queue and multi-technical platform samples by determining four types of subtypes, stability and unification of cross-cancer type typing are realized, and a new standardized diagnosis and treatment thought is provided. The molecular subtype determined by the method is used for in-vitro drug response prediction for non-diagnosis / treatment purposes, a scientific basis is provided for risk stratification and individualized medication research, precise treatment research is further promoted, and clinical guidance value is outstanding.

The invention discloses a tumor molecular typing method based on EMT heterogeneity and application of the tumor molecular typing method in cancer evolution visualization. According to the invention, molecular typing is carried out on para-carcinoma tissues and corresponding cancer tissues according to EMT characteristics, the para-carcinoma tissues and the corresponding cancer tissues are divided into three EHBMT subtypes of epithelium type, mesenchymal type and intermediate type, then changes of the para-carcinoma tissues and the corresponding cancer tissue subtypes from the same donor are analyzed, and visualization of tumor evolution is realized. According to the method, tumor evolution can be visualized from the perspective of EMT characteristics, personalized precise medical treatment of the patient is guided, and the method has important significance in improving prognosis of the patient.

The application provides a chronic hepatitis B treatment method and device based on a molecular typing model, and the method comprises the following steps: obtaining a tissue sample of a chronic hepatitis B patient; determining the type of chronic hepatitis B of the chronic hepatitis B patient according to the tissue sample of the chronic hepatitis B patient based on a constructed molecular typing model; and determining the targeted treatment drug for the chronic hepatitis B patients of each type according to the type of chronic hepatitis B of the chronic hepatitis B patient. The application can perform molecular typing on the tissue sample of the chronic hepatitis B patient through the construction of the molecular typing model and the molecular typing model, and give the targeted treatment drug according to the type of chronic hepatitis B of the chronic hepatitis B patient. From the perspective of disease heterogeneity, the application provides a new idea for the treatment of drug-resistant patients and a new stratification suggestion for CHB patients.

The application relates to the field of clinical molecular typing, and discloses a novel PCOS subphenotype precision diagnosis and treatment platform, a case sample inclusion and cohort construction module, a data acquisition and processing module, a key feature screening module, 12-dimensional feature data of a patient used for subphenotype clustering, an unsupervised learning module, a K-Means clustering algorithm used for unsupervised clustering of 12-dimensional feature data of the case, a PCOS patient group divided into five new subtypes, an XGBoost model construction module, the five new subtypes as classification labels, and an XGBoost model constructed, and a typing prediction module, the XGBoost model constructed used for prediction of PCOS subphenotypes. The application provides a new fine-grained typing, a prediction model and a precision treatment scheme based on subtypes, and is suitable for subtype differentiation and treatment guidance of PCOS patients.

This invention relates to a molecular typing kit for peripheral blood neutrophils and its application in the early diagnosis of lung cancer, belonging to the field of oncology technology. The kit comprises a target sequence hybridization probe and a fluorescent reporter probe; the nucleotide sequence of the target sequence hybridization probe is shown in SEQ ID NO: 11-25; the nucleotide sequence of the fluorescent reporter probe is shown in SEQ ID NO: 26. This invention designs the target sequence hybridization probe so that one part hybridizes with the target gene and the other part hybridizes with the fluorescent reporter probe. The fluorescence value of the fluorescent reporter probe can identify or differentiate target cells. Using this kit, neutrophils can be identified or classified into neutrophil subsets that are positive for CXCL8, LYZ, IL1R2, S100A12, and IFI16 genes. These gene-positive neutrophil subsets can be used to diagnose early-stage cancer.

The application discloses a cancer molecular marker prediction method based on multi-omics and intelligent feature mining, and belongs to the technical field of bioinformatics and artificial intelligence; the method comprises the following steps: collecting multi-omics data of cancer samples, including genomic, transcriptomic, epigenetic, proteomic and metabolomic data; performing quality control and pretreatment on the data; performing intelligent feature mining by adopting difference analysis, dimension reduction algorithm and feature fusion network; integrating biological networks to construct a multi-view graph neural network prediction model; identifying key molecular markers and performing verification; the application can effectively integrate multi-level omics data, mine molecular markers with biological significance, and establish a high-precision and high-explainability prediction model; the application provides an effective technical means for early diagnosis, molecular typing, prognosis evaluation and individualized treatment of cancer, and has important scientific significance and clinical application value.

The application belongs to the technical field of biological pharmacy, and provides a set of esophageal cancer methylation early screening markers and application thereof, the markers being any one or a combination of two or more of ZNF693, MMP14, JAG1, RUNX1 or NOTCH1 gene sequences or gene fragments containing at least one CpG methylation site; the application also discloses application of the set of biomarkers in preparation of a detection kit for diagnosing and / or evaluating the methylation degree of esophageal cancer or in screening of drugs for treating and / or relieving esophageal cancer. The application can effectively identify cancer patients by quantifying the dynamic change of the methylation level, and reduce the risk of missed detection caused by tumor heterogeneity; by establishing a high-throughput and standardized detection process, the application can provide a precise molecular typing tool for early intervention of esophageal cancer; the application overcomes the limitations of traditional technology, such as insufficient detection sensitivity for early cancer and dependence on invasive operation, and can promote clinical transformation of "early screening and early diagnosis".